| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 28.4 | 26.3 |
| Gross profit | 26.3 | 24.5 |
| Net income | -1.4 | -30.4 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +8.0% |
|---|---|
| Gross margin | 92.6% |
| Operating margin | 2.6% |
10-Q filed with the SEC, NASDAQ: SMTI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Sanara MedTech Inc.: key numbers
- Share price
- $32.76Close, Nov 16
- Market cap
- $301M
- Shares outstanding
- 9.18MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Sanara MedTech Inc.
All →Sanara MedTech Financial Results
Sanara MedTech reported Q3 2026 net revenue of $28.4 million, an 8% increase year-over-year, and Adjusted EBITDA of $5.6 million. The company recorded a net loss from continuing operations of $1.3 million, which included $3.0 million in legal and advisory costs related to its pending merger with MiMedx Group, Inc.
- Term
- Q3 2026
Sanara MedTech Divestiture for $2M
Sanara MedTech Inc. sold all assets of its wholly owned subsidiary, Tissue Health Plus, LLC (THP), to an unrelated third party. The transaction included THP's business software products and intellectual property for approximately $2.0 million plus certain earnout rights.
- Value
- $2M
Sanara MedTech M&A Deal with MiMedx Group, Inc.
Sanara MedTech and MiMedx Group received a 'Second Request' for information from the FTC regarding their pending merger. This request extends the HSR Act waiting period until 30 days after both parties substantially comply with the request, unless terminated earlier by the FTC.
- Counterparty
- MiMedx Group, Inc.
Sanara MedTech M&A Deal with MiMedx Group, Inc.
Sanara MedTech shareholders approved the previously announced merger agreement with MiMedx Group, Inc., under which Sanara will become a wholly-owned subsidiary of MiMedx. The filing also provides a regulatory update noting that MiMedx voluntarily withdrew its HSR Act notification to allow the FTC additional time for review. The merger remains subject to customary closing conditions.
- Counterparty
- MiMedx Group, Inc.